Sugar chain added GLP-1 peptide

Details Sugar chain added GLP-1 peptide Sugar chain added GLP-1 peptide

2011-07-26

2011-07-26

Landsman, Robert (Department: 1646)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S020900

Reexamination Certificate

active

07985731

ABSTRACT:
The present invention relates to an oligosaccharide chain added GLP-1 peptide that has higher stability in blood than that of GLP-1 and, preferably, exhibits higher activity of controlling blood-sugar levels than that of GLP-1. The present invention relates to an oligosaccharide chain added GLP-1 peptide having GLP-1 activity, wherein at least one amino acid is substituted with an oligosaccharide chain added amino acid, in: (a) GLP-1; (b) a peptide having the amino acid sequence of GLP-1 with deletion, substitution or addition of one or several amino acids; or (c) a GLP-1 analog.

REFERENCES:
patent: 2005/0222382 (2005-10-01), Kajihara
patent: 2007/0060543 (2007-03-01), Kajihara et al.
patent: 1 961 764 (2008-08-01), None
patent: 2005-095331 (2005-10-01), None
patent: 2006-520818 (2006-09-01), None
patent: WO 2004/005330 (2004-01-01), None
patent: WO 2005/010053 (2005-02-01), None
patent: WO 2006/010143 (2006-01-01), None
patent: WO 2007/063907 (2007-06-01), None
“Short Communication: Renal Tubular Vacuolation in Animals Treated with Polyethylene-Glycol-Conjugated Proteins”—A. Bendele et al.—Toxicological Sciences 42, (1998)—pp. 152-157.
“Isolation and Characterization of Exendin-4, an Exendin-3 Analogue, fromHeloderma suspectumVenom”—J. Eng et al.—The Journal of Biological Chemistry—vol. 267, No. 11, Issue of Apr. 15, 1992—pp. 7402-7405.
“Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes”—C.A. Schnabel et al.—Vascular Health and Risk Management 2006:2(I) pp. 69-77.
“Efficacy and Safety of Incretin Therapy in Type 2 Diabetes: Systematic Review and Meta-analysis”—R.E. Amori et al.—JAMA—Aug. 27, 2008—pp. 194-206.
“β-Cell Failure in Diabetes and Preservation by Clinical Treatment”—B.L. Wajchenberg—Endocrine Reviews 28(2): 187-218—Copyright 2007 by The Endocrine Society.
Journal of the Japan Diabetes Society, vol. 51, Supplemental 1, Abstracts of 51stAnnual Meeting of the Japan Diabetes Society—May 22-24, 2008; Published on Apr. 25, 2008—pp. 1-2.
Translation of Journal of the Japan Diabetes Society, vol. 51, Supplemental 1, Abstracts of 51stAnnual Meeting of the Japan Diabetes Society—May 22-24, 2008; Published on Apr. 25, 2008—pp. 1-2.
Meurer, Janet A. et al., Properties of Native and in Vitro Glycosylated Forms of the Glucagon-Like Peptide-1 Receptor Antagonist Exending (9-39—; Metabolism, vol. 48, No. 5 (Jun. 1999); pp. 716-724.

Affiliated with

Also associated with

Rating

Sugar chain added GLP-1 peptide does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Sugar chain added GLP-1 peptide, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sugar chain added GLP-1 peptide will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2636206